1420
M.-A. Virolleaud, O. Piva / Tetrahedron Letters 48 (2007) 1417–1420
13. Basu, S.; Waldmann, H. J. Org. Chem. 2006, 71, 3977–
References and notes
3979.
14. Schmidt, B.; Nave, S. Chem. Commun. 2006, 2489–
2491.
1. (a) Grubbs, R. H.; Chang, S. Tetrahedron 1998, 54, 4413–
4450; (b) Furstner, A. Angew. Chem., Int. Ed. 2000, 39,
¨
15. Ghosh, S.; Raychandhuri, S. R.; Salomon, R. G. J. Org.
Chem. 1987, 52, 83–90.
3012–3043; (c) Schrock, R. R.; Hoveyda, A. H. Angew.
Chem., Int. Ed. 2003, 42, 4592–4633.
2. Nobel lecture 2005: (a) Chauvin, Y. Angew. Chem., Int.
Ed. 2006, 45, 3740–3747; (b) Schrock, R. R. Angew.
Chem., Int. Ed. 2006, 45, 3748–3759; (c) Grubbs, R. H.
Angew. Chem., Int. Ed. 2006, 45, 3760–3765.
16. Compound 11a: 78%. 1H NMR (300 MHz, CDCl3):
d = 1.93 (quin, J = 7.1 Hz, 2H), 2.12–2.30 (m, 4H), 3.39
(t, J = 6.9 Hz, 2H), 3.98 (quin, J = 4.7 Hz, 1H), 4.20 (sl,
2H), 5.58–5.93 (m, 4H). 13C NMR (75 MHz, CDCl3):
d = 30.9, 31.4, 32.2, 33.4, 65.9, 73.9, 124.1, 126.5, 130.2,
132.2. HRMS (CI) calcd for C10H15BrO–H+ = 229.0228,
found 229.0221.
3. Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. Angew. Chem.,
Int. Ed. 2005, 44, 4490–4527.
4. Recent applications in total synthesis: (a) Pfeiffer, M. W.
B.; Phillips, A. J. J. Am. Chem. Soc. 2005, 127, 5334–5335;
(b) Kim, S.; Ko, H.; Lee, T.; Kim, D. J. Org. Chem. 2005,
70, 5756–5759; (c) Mehta, G.; Shinde, H. M. Chem.
Commun. 2005, 3703–3705; (d) Nicolaou, K. C.; Harisson,
S. T. Angew. Chem., Int. Ed. 2006, 45, 3256–3260; (e)
Barluenga, S.; Dakas, P.-Y.; Ferandin, Y.; Meijer, L.;
Winssinger, N. Angew. Chem., Int. Ed. 2006, 45, 3951–
3954; (f) Virolleaud, M.-A.; Menant, C.; Fenet, B.; Piva,
O. Tetrahedron Lett. 2006, 47, 5127–5130.
5. (a) Randl, S.; Blechert, S. Tandem Ring-closing Meta-
thesis. In Handbook of Metathesis; Grubbs, R. H., Ed.;
Wiley, VCH: Weiheim, 2003; Vol. 2, pp 151–175; (b)
Aitken, S. G.; Abell, A. D. Aust. J. Chem. 2005, 58, 3–13;
(c) Fukumoto, H.; Takahashi, K.; Ishihara, J.; Hatake-
yama, S. Angew. Chem., Int. Ed. 2006, 45, 2731–2734; (d)
Kummer, D. A.; Brenneman, J. B.; Martin, S. F. Org.
Lett. 2005, 7, 4621–4623; (e) Royer, F.; Vilain, C.; Elka¨ım,
L.; Grimaud, L. Org. Lett. 2003, 5, 2007–2009.
Compound 11b: 69%. 1H NMR (300 MHz, CDCl3):
d = 0.04 (s, 6H), 0.90 (s, 9H), 1.50–1.80 (m, 2H), 1.94–
2.37 (m, 4H), 3.62 (t, J = 6.4 Hz, 2H), 3.98 (dt, J = 6.2–
3.7 Hz, 1H), 4.20 (sl, 2H), 5.55 (dd, J = 15.4(E)-6.2 Hz,
1H), 5.68–5.87 (m, 3H). 13C NMR (75 MHz, CDCl3):
d = À5.0, 18.6, 26.2, 28.9, 31.4, 32.5, 62.8, 65.9, 74.2,
124.3, 126.5, 131.0, 132.3. HRMS (CI) calcd for
C16H30O2Si–H+ = 281.1937, found 281.1936.
Compound 11c: 73%. 1H NMR (300 MHz, CDCl3):
d = 0.89 (t, J = 7.1 Hz, 3H), 1.17–1.46 (m, 18H), 1.93–
2.18 (m, 4H), 3.98 (dt, J = 6.2–3.7 Hz, 1H), 4.24 (sl, 2H),
5.52 (dd, J = 15.4(E)-6.2 Hz, 1H), 5.14–5.96 (m, 3H). 13C
NMR (75 MHz, CDCl3): d = 14.4, 23.0, 29.4, 29.5, 29.7,
29.8, 29.9, 30.0, 30.1, 31.4, 32.2, 32.7, 66.0, 74.3, 124.3,
126.5, 130.6, 133.0. HRMS (EI) calcd for C18H32O =
264.2453, found 264.2450.
Compound 11d: 40%. 1H NMR (300 MHz, CDCl3):
d = 2.05–2.16 (m, 2H), 3.96 (d, J = 7.2 Hz, 2H), 4.03–
4.12 (m, 1H), 4.23 (sl, 2H), 5.70–5.89 (m, 3H), 5.90–6.03
(m, 1H). 13C NMR (75 MHz, CDCl3): d = 30.9, 32.5, 66.0,
72.9, 123.9, 126.6, 127.3, 135.6. HRMS (CI) calcd for
C8H11BrO–H+ = 200.9915, found 200.9917.
6. Virolleaud, M.-A.; Bressy, C.; Piva, O. Tetrahedron Lett.
2003, 44, 8081–8084.
7. Virolleaud, M.-A.; Piva, O. Synlett 2004, 2087–2090.
8. Compound 8: 1H NMR (300 MHz, CDCl3): d = 0.80–0.96
(m, 3H), 1.11–1.43 (m, 4H), 1.96–2.14 (m, 2H), 2.34–2.57
(m, 2H), 4.87 (q, J = 7.3 Hz, 1H), 5.53–5.65 (m, 1H), 5.83
(dt, J = 15.3(E)-6.8 Hz, 1H), 6.04 (dt, J = 9.8–1.7 Hz,
1H), 6.88 (dt, J = 9.8–4.2 Hz, 1H). 13C NMR (75 MHz,
CDCl3): d = 14.1, 22.5, 30.1, 31.1, 32.0, 78.6, 121.7, 126.9,
136.0, 145.1, 164.5.
Compound 11e: 61%. 1H NMR (300 MHz, CDCl3):
d = 2.06–2.30 (m, 2H), 4.18 (quin, J = 4.8 Hz, 1H), 4.27
(s, 2H), 5.75 (dm, J = 10.3–1.2 Hz, 1H), 5.85 (dm,
J = 10.3–2.5 Hz, 1H), 6.24 (dd, J = 16.0(E)-5.8 Hz, 1H),
6.62 (d, J = 16.0 Hz, 1H), 7.17–7.40 (m, 5H). 13C NMR
(75 MHz, CDCl3): d = 31.4, 66.0, 74.1, 124.2, 126.6, 126.8,
127.9, 128.8, 130.2, 130.8, 137.1. HRMS (CI) calcd for
C13H14O–H+ = 185.0966, found 185.0960.
Compound 9: 1H NMR (300 MHz, CDCl3): d = 0.80–0.96
(m, 3H), 1.11–1.43 (m, 4H), 1.96–2.14 (m, 2H), 2.34–2.57
(m, 2H), 5.03 (t, J = 6.4 Hz, 1H), 5.35 (dt, J = 15.3(E)-
7.3 Hz, 1H), 5.60 (dt, J = 15.3(E)-6.8 Hz, 1H), 6.13 (dd,
J = 5.7–2.0 Hz, 1H), 7.44 (dd, J = 5.7–1.4 Hz, 1H). 13C
NMR (75 MHz, CDCl3): d = 14.1, 22.3, 31.5, 32.4, 36.4,
83.2, 122.0, 122.2, 136.3, 156.4, 173.3.
Compound 12e: 12%. 1H NMR (300 MHz, CDCl3):
d = 2.51 (t, J = 6.5 Hz, 2H), 4.58–4.76 (m, 2H), 4.98 (m,
1H), 5.85 (dd, J = 6.2–1.3 Hz, 1H), 5.93 (dd, J = 6.4–
1.6 Hz, 1H), 6.24 (dt, J = 15.8(E)-7.2 Hz, 1H), 6.48 (d,
J = 15.8 Hz, 1H), 7.17–7.40 (m, 5H).
Compound 13: 24%. 1H NMR (300 MHz, CDCl3):
d = 1.98–2.23 (m, 4H), 4.00–4.10 (m, 2H), 4.23 (sl, 4H),
5.72 (dm, J = 10.3 Hz, 2H), 5.78–5.87 (m, 4H). 13C NMR
9. (a) Quinn, K. J.; Isaacs, A. K.; Arvary, R. A. Org. Lett.
2004, 6, 4143–4145; (b) Quinn, K. J.; Isaacs, A. K.;
DeChristopher, B. A.; Szklarz, S. C.; Arvary, R. A. Org.
Lett. 2005, 7, 1243–1245.
(75 MHz, CDCl3):
2
diastereomers: d = 31.2 and
31.3, 66.0 and 66.1, 73.4 and 73.7, 124.2, 126.6, 131.6
and 131.9.
10. Nelson, S. G.; Cheung, W. S.; Kassick, A. J.; Hilfiker, M.
A. J. Am. Chem. Soc. 2002, 124, 13654–13655.
11. Crimmins, M. T.; Zhang, Y.; Diaz, F. A. Org. Lett. 2006,
8, 2369–2372.
12. (a) Hoye, T. R.; Jeffrey, C. S.; Tennakoon, M. A.; Wang,
J.; Zhao, H. J. Am. Chem. Soc. 2004, 126, 10210–10211;
(b) Wallace, D. J. Angew. Chem., Int. Ed. 2005, 44, 1912–
1915.
Compound 14: 23%. 1H NMR (300 MHz, CDCl3):
d = 1.96–2.20 (m, 2H), 2.23–2.40 (m, 2H), 4.00 (quin,
J = 4.8 Hz, 1H), 4.20 (sl, 2H), 4.53–4.70 (m, 2H), 4.85 (sl,
1H), 5.47–5.96 (m, 6H). 13C NMR (75 MHz, CDCl3):
d = 30.1, 31.4, 66.0, 74.1, 75.6, 85.9, 124.3, 126.7, 127.2,
127.9, 139.7, 133.6.